Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Pamine
Overview
What is Pamine?
Pamine 2.5 mg/Pamine Forte 5 mg
The chemical name for methscopolamine bromide is 3-Oxa-9-azoniatricyclo [3.3.1.0]nonane, 7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9, 9-dimethyl-, bromide, [7()-(1α, 2β, 4β, 5α, 7β)]- and the molecular weight is 398.30.
The structural formula is represented below:
Pamine 2.5 mg
Pamine Forte 5 mg
Inactive ingredients: microcrystalline cellulose, pregelatinized starch, magnesium stearate.
Contains no lactose.
What does Pamine look like?
What are the available doses of Pamine?
Sorry No records found.
What should I talk to my health care provider before I take Pamine?
Sorry No records found
How should I use Pamine?
Adjunctive therapy for the treatment of peptic ulcer.
METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS.
The average dosage of Tablets is 2.5 mg one-half hour before meals and 2.5 to 5 mg at bedtime. A starting dose of 12.5 mg daily will be clinically effective in most patients without the production of appreciable side effects.
If the patient is experiencing symptoms such as severe abdominal pain or cramping which demand prompt relief, the drug may be started on a daily dosage of 20 mg, administered in doses of 5 mg one-half hour before meals and at bedtime. If very unpleasant side effects develop promptly, the daily dosage should be reduced. If neither symptomatic relief nor side effects appear, the daily dosage may be increased. Some patients have tolerated 30 mg daily with no unpleasant reactions.
Patients whose dosage has been reduced to eliminate or modify side effects often continue to show adequate response both subjectively in relief of symptoms and objectively as measured by antisecretory effects.
The ultimate aim of therapy is to arrive at a dosage which provides maximal clinical effectiveness with a minimum of unpleasant side effects. Many patients report no side effects on a dosage which gives complete relief of symptoms. On the other hand, some patients have reported severe side effects without appreciable symptomatic relief. Such patients must be considered unsuited for this therapy. Usually they have been or will prove to be similarly intolerant to other anticholinergic drugs. If methscopolamine bromide is to be used in a patient who gives a history of such intolerance, it should be started at a low dosage.
What interacts with Pamine?
Glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
Pamine 2.5 mg/Pamine Forte 5 mg
What are the warnings of Pamine?
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
In the presence of high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with drug use.
Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.
Methscopolamine bromide may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.
With overdosage, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.
What are the precautions of Pamine?
1. General precautions
Use Tablets with caution in the elderly and in all patients with: autonomic neuropathy; hepatic or renal disease; or ulcerative colitis –large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason precipitate or aggravate "toxic megacolon," a serious complication of the disease.
The drug also should be used with caution in patients having hyperthyroidism, coronary heart disease, congestive heart failure, tachyrhythmia, tachycardia, hypertension, or prostatic hypertrophy.
2. Information for patient
See statement under .
3. Laboratory tests
Progress of the peptic ulcer under treatment should be followed by upper gastrointestinal contrast radiology or endoscopy to insure healing. Stool tests for occult blood and blood hemoglobin or hematocrit values should be followed to rule out bleeding from the ulcer.
4. Drug interactions
Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. Concomitant administration with antacids may interfere with the absorption of methscopolamine bromide.
5. Carcinogenesis, mutagenesis, impairment of fertility
No long-term studies in animals have been performed to evaluate carcinogenic potential.
6. Pregnancy
7. Nursing mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methscopolamine bromide is administered to a nursing woman.
Anticholinergic drugs may suppress lactation.
8. Pediatric use
Safety and efficacy in children have not been established.
What are the side effects of Pamine?
The following adverse reactions have been observed, but there is not enough data to support an estimate of frequency.
Cardiovascular:
Allergic:
CNS:
Special Senses:
Renal:
Gastrointestinal:
Dermatologic:
Miscellaneous:
What should I look out for while using Pamine?
Glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
Pamine 2.5 mg/Pamine Forte 5 mg
In the presence of high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with drug use.
Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.
Methscopolamine bromide may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.
With overdosage, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.
What might happen if I take too much Pamine?
The symptoms of overdosage with Tablets progress from intensification of the usual side effects to CNS disturbances (from restlessness and excitement to psychotic behavior), circulatory changes (flushing, fall in blood pressure, circulatory failure), respiratory failure, paralysis, and coma.
Measures to be taken are (1) induction of emesis and (2) injection of physostigmine 0.5 to 2 mg intravenously, and repeated as necessary up to a total of 5 mg. Fever may be treated symptomatically (alcohol sponging, ice packs). Excitement of a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100-200 mL of a 2% solution) by rectal infusion. In the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.
The oral LD in rats is 1,352 to 2,617 mg/kg.
No data is available on the dialyzability of methscopolamine bromide.
How should I store and handle Pamine?
Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].ArrayManufactured by:Hi-Tech Pharmacal Co., Inc.Amityville, NY 11701Made in U.S.A.ArrayStore at 20-25°C (68-77°F) [see USP Controlled Room Temperature].ArrayManufactured by:Hi-Tech Pharmacal Co., Inc.Amityville, NY 11701Made in U.S.A.ArrayStore at 20-25°C (68-77°F) [see USP Controlled Room Temperature].ArrayManufactured by:Hi-Tech Pharmacal Co., Inc.Amityville, NY 11701Made in U.S.A.ArrayStore at 20-25°C (68-77°F) [see USP Controlled Room Temperature].ArrayManufactured by:Hi-Tech Pharmacal Co., Inc.Amityville, NY 11701Made in U.S.A.ArrayStore at 20-25°C (68-77°F) [see USP Controlled Room Temperature].ArrayManufactured by:Hi-Tech Pharmacal Co., Inc.Amityville, NY 11701Made in U.S.A.ArrayStore at 20-25°C (68-77°F) [see USP Controlled Room Temperature].ArrayManufactured by:Hi-Tech Pharmacal Co., Inc.Amityville, NY 11701Made in U.S.A.ArrayStore at 20-25°C (68-77°F) [see USP Controlled Room Temperature].ArrayManufactured by:Hi-Tech Pharmacal Co., Inc.Amityville, NY 11701Made in U.S.A.ArrayPamine 2.5 mgBottles of 100 (NDC 10337-061-01)Pamine Forte 5 mgDose Pack (5 blisters of 12 tablets)Box of 60 (NDC 10337-062-06)Pamine 2.5 mgBottles of 100 (NDC 10337-061-01)Pamine Forte 5 mgDose Pack (5 blisters of 12 tablets)Box of 60 (NDC 10337-062-06)Pamine 2.5 mgBottles of 100 (NDC 10337-061-01)Pamine Forte 5 mgDose Pack (5 blisters of 12 tablets)Box of 60 (NDC 10337-062-06)Pamine 2.5 mgBottles of 100 (NDC 10337-061-01)Pamine Forte 5 mgDose Pack (5 blisters of 12 tablets)Box of 60 (NDC 10337-062-06)
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia.
Non-Clinical Toxicology
Glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.Pamine 2.5 mg/Pamine Forte 5 mg
In the presence of high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with drug use.
Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.
Methscopolamine bromide may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.
With overdosage, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.
Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. Concomitant administration with antacids may interfere with the absorption of methscopolamine bromide.
Use Tablets with caution in the elderly and in all patients with: autonomic neuropathy; hepatic or renal disease; or ulcerative colitis –large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason precipitate or aggravate "toxic megacolon," a serious complication of the disease.
The drug also should be used with caution in patients having hyperthyroidism, coronary heart disease, congestive heart failure, tachyrhythmia, tachycardia, hypertension, or prostatic hypertrophy.
The following adverse reactions have been observed, but there is not enough data to support an estimate of frequency.
Cardiovascular:
Allergic:
CNS:
Special Senses:
Renal:
Gastrointestinal:
Dermatologic:
Miscellaneous:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).